Transparent tracker comparing US drug prices vs other countries and trade-offs

Transparent tracker comparing US drug prices vs other countries and trade-offs targets a $4.2B = 21,000 potential institutional customers × $200K ACV (governments, payers, large NGOs, and procurement agencies needing enterprise pricing and concession analytics) total addressable market with medium saturation and a year-over-year growth rate of 12% YoY (healthcare analytics and transparency tools growth; source: industry reports including McKinsey and Deloitte analyses of healthcare data markets, 2022-2024).

Key trends driving demand: Global transparency initiatives are increasing release of procurement and pricing documents — this creates an expanding pool of primary sources to ingest and analyze.; Policymakers and payers face political pressure to justify drug prices — they need audit-ready evidence and tools to benchmark deals against international comparators.; Advances in LLMs and entity extraction make it feasible for small teams to parse multilingual contracts and extract structured concession terms at scale.; Open-source data movements and demand for public-facing tools mean a hybrid free+paid model can drive adoption and referrals from journalists and advocacy groups..